StonvexLoading…
StonvexStonvexStonvexCore line items from UBS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2021 2021-12-31 | Annual 2020 2020-12-31 | Annual 2019 2019-12-31 | Annual 2018 2018-12-31 |
|---|---|---|---|---|
Revenue | $35.39B | $33.08B | $28.97B | $30.33B |
Operating Income | $9.48B | $8.15B | $5.58B | $5.99B |
Net Income | $7.49B | $6.57B | $4.31B | $4.52B |
EPS (Diluted) | $2.06 | $1.77 | $1.14 | $1.18 |
Total Assets | $1.12T | $1.13T | $972.19B | $958.50B |
Total Liabilities | $1.06T | $1.07T | $917.52B | $905.43B |
Cash & Equivalents | $207.88B | $173.53B | $119.87B | $126.08B |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 3.40B | 3.55B | 3.62B | 3.69B |